Cantor Fitzgerald Initiates Coverage On Skye Bioscience with Overweight Rating, Announces Price Target of $21
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has initiated coverage on Skye Bioscience (NASDAQ:SKYE) with an Overweight rating and a price target of $21.
May 23, 2024 | 3:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has initiated coverage on Skye Bioscience with an Overweight rating and a price target of $21. This positive analyst rating could boost investor confidence and potentially drive the stock price up in the short term.
The initiation of coverage with an Overweight rating and a specific price target of $21 by a reputable firm like Cantor Fitzgerald is likely to attract investor attention and increase buying interest in Skye Bioscience. This could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100